About
Renal Therapies
Areas of Focus
Categories
Small Molecule PharmaceuticalChina
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
6
As Collaborator
0
Total Enrollment
973
By Phase
PHASE3: 2PHASE2: 2PHASE1: 2
By Status
COMPLETED: 3RECRUITING: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT06933472Lead Sponsor
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
PHASE3Recruiting
264 participants
Started: Jun 13, 2025 · Completed: Jan 10, 2027
NCT06712654Lead Sponsor
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia
PHASE2Not yet recruiting
144 participants
Started: Apr 10, 2025 · Completed: Dec 30, 2025
NCT06666283Lead Sponsor
A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients
PHASE1Recruiting
18 participants
Started: Feb 27, 2025 · Completed: Sep 25, 2025
NCT06308523Lead Sponsor
A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in Healthy Chinese Participants
PHASE1Completed
18 participants
Started: Mar 18, 2024 · Completed: May 13, 2024
NCT07030595Lead Sponsor
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
PHASE3Completed
474 participants
Started: Jun 12, 2023 · Completed: May 30, 2025
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...